Why combination drug treatment ineffective in cancer clinical trials

December 5, 2013, University of Alberta Faculty of Medicine & Dentistry

Medical researchers at the University of Alberta have discovered that combination drug therapy didn't work well in clinical trials for cancer patients because one drug was making the other drug ineffective.

Faculty of Medicine & Dentistry researcher Michael Sawyer and his colleagues, including first author Vijaya Damaraju, recently published their findings in the peer-reviewed journal, Clinical Cancer Research.

In the '80s and '90s, cancer research focused on finding out which proteins "drove" cancers. New drugs targeting these proteins worked well by themselves, and some in the field believed combining the new drugs with the older chemotherapy drugs would work better than either drug by itself.

"So the pharmaceutical industry developed a combination of drugs in which we thought we were giving two drugs at once, but in actual fact the one drug we were giving was completely blocking the actions of the other drug," said Sawyer, who works in the Faculty's Department of Oncology.

"The old chemotherapy drugs required special proteins to get inside of cells to work. What our team discovered is that the new chemotherapy drugs prevented these proteins from carrying the old into the cell. No one was able to figure out why this combination of drugs didn't work, but now we have discovered what went wrong." Sawyer says the findings will guide oncologists about how drugs should be combined, or whether certain drugs should be combined at all.

"This will save us from doing millions of dollars in that have no chance of working out. These findings show oncologists we have to be careful about which drugs should be combined. You have to think about how they actually work, especially in ways which no one understood before.

"Our research was actually like peeling an onion. Once we figured out the answer to one question, then other things the drugs did make more sense. Ultimately, the findings mean we'll be able to design better combination drug therapies. We'll know which drugs to combine, and when and how drugs can be combined. This will require more precise scheduling and dosing than what we've done to date."

He stressed the only patients impacted were those in clinical trials – the therapy had not yet become common clinical practice because it wasn't working the way oncologists had hoped. And for those patients who took part in the clinical trials, the one chemotherapy was still very effective – so those patients still received excellent care and drugs that properly targeted their cancers.

Sawyer and his team are continuing their research in this area. Their research was funded by the former Alberta Cancer Board, the Alberta Cancer Foundation and Alberta Innovates – Health Solutions.

Explore further: Discovery paves way for personalized cancer treatment

Related Stories

Discovery paves way for personalized cancer treatment

November 18, 2013
A prostate cancer researcher at the University of Alberta and his team have discovered how to improve currently available cancer drugs so the medication could be personalized for individual patients.

Sanofi abandons two drugs after trial failures

June 3, 2013
Drugmaker Sanofi is abandoning two drugs in the late stages of development after trials revealed they weren't more effective than other therapies.

Re-thinking cancer treatment

November 18, 2013
A new treatment approach for tackling cancer of the food pipe (oesophagus) has been developed by researchers at Cardiff and Velindre NHS Trust.

Study explains why drug may help more cancer patients

November 18, 2013
(Medical Xpress)—Recently some intriguing data has suggested that breast cancer patients whose tumors appear insensitive to a class of drugs known as anti-HER2 medications (the drug trastuzumab, marketed as Herceptin, is ...

Drug combination therapy causes cancer cells to 'eat themselves'

November 5, 2013
Results from a recent preclinical study have shown that a new drug combination therapy being developed at Virginia Commonwealth University Massey Cancer Center effectively killed colon, liver, lung, kidney, breast and brain ...

Biologists ID new cancer weakness

November 14, 2013
About half of all cancer patients have a mutation in a gene called p53, which allows tumors to survive and continue growing even after chemotherapy severely damages their DNA.

Recommended for you

'Hijacker' drives cancer in some patients with high-risk neuroblastoma

January 23, 2018
Researchers have identified mechanisms that drive about 10 percent of high-risk neuroblastoma cases and have used a new approach to show how the cancer genome "hijacks" DNA that regulates other genes. The resulting insights ...

Enzyme inhibitor combined with chemotherapy delays glioblastoma growth

January 23, 2018
In animal experiments, a human-derived glioblastoma significantly regressed when treated with the combination of an experimental enzyme inhibitor and the standard glioblastoma chemotherapy drug, temozolomide.

Scientists block the siren call of two aggressive cancers

January 23, 2018
Aggressive cancers like glioblastoma and metastatic breast cancer have in common a siren call that beckons the bone marrow to send along whatever the tumors need to survive and thrive.

Researchers identify a protein that keeps metastatic breast cancer cells dormant

January 23, 2018
A study headed by ICREA researcher Roger Gomis at the Institute for Research in Biomedicine (IRB Barcelona) has identified the genes involved in the latent asymptomatic state of breast cancer metastases. The work sheds light ...

Workouts may boost life span after breast cancer

January 22, 2018
(HealthDay)—Longer survival after breast cancer may be as simple as staying fit, new research shows.

Boosting cancer therapy with cross-dressed immune cells

January 22, 2018
Researchers at EPFL have created artificial molecules that can help the immune system to recognize and attack cancer tumors. The study is published in Nature Methods.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.